Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « June » « 2025 » M T W T F S S 26 27 28 29 30 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4 5 6   - « June » « 2025 » M T W T F S S 26 27 28 29 30 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4 5 6   Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Morise, Masahiro
LIBRETTO-001, NCT03157128 / 2017-000800-59: A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer Jan 2022 - Dec 2022 : Submission for lung cancer Apr 2022 - Dec 2022 : Approval in China for RET+NSCLC, medullary thyroid cancer and thyroid cancer From LIBRETTO-001 trial in RET fusion-positive NSCLC Aug 2020 - Aug 2020: From LIBRETTO-001 trial in RET fusion-positive NSCLC Granted for advanced RET fusion+ve 2L thyroid cancer [LIBRETTO-001] Oct 2018 - Oct 2018: Granted for advanced RET fusion+ve 2L thyroid cancer [LIBRETTO-001] Updated interim data for RET mut medullary & RET fusion thyroid cancers [LIBRETTO-001] Oct 2018 - Oct 2018: Updated interim data for RET mut medullary & RET fusion thyroid cancers [LIBRETTO-001] Granted for 1L RET-mutant medullary thyroid cancer Sep 2018 - Sep 2018: Granted for 1L RET-mutant medullary thyroid cancer Granted for 2L metastatic RET-fusion +ve NSCLC Sep 2018 - Sep 2018: Granted for 2L metastatic RET-fusion +ve NSCLC More	Active, not recruiting	1/2	857	Europe, Canada, Japan, US, RoW	LOXO-292, Selpercatinib, LY3527723	Eli Lilly and Company, Loxo Oncology, Inc.	Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Any Solid Tumor	02/25	02/26
TRIDENT-1, NCT03093116 / 2016-003616-13: A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements Jan 2025 - Jan 2025 : Approval in EU for adv ROS1+ve NSCLC, adv NTRK+ve solid tumors Jan 2023 - Dec 2023 : Data readout from P1/2 TRIDENT-1 trial for ROS1 NSCLC and NTRK+ solid tumors Jul 2023 - Dec 2023 : Approval for ROS1+ NSCLC Jan 2023 - Dec 2023: Approval in US for 2L NSCLC Top line data across ROS1-positive TKI-naïve and TKI-pretreated NSCLC cohorts in TRIDENT-1 trial Apr 2022 - Apr 2022: Top line data across ROS1-positive TKI-naïve and TKI-pretreated NSCLC cohorts in TRIDENT-1 trial NMPA granted in patients with for the treatment of patients with ROS1-positive NSCLC Feb 2022 - Feb 2022: NMPA granted in patients with for the treatment of patients with ROS1-positive NSCLC Presentation of Trident -1 data for the treatment of NSCLC in AACR-NCI-EORTC 2021 Oct 2021 - Oct 2021: Presentation of Trident -1 data for the treatment of NSCLC in AACR-NCI-EORTC 2021 Granted in patients with NTRK-positive, TKI-pretreated advanced solid tumors Oct 2021 - Oct 2021: Granted in patients with NTRK-positive, TKI-pretreated advanced solid tumors Granted for ROS1-positive advanced NSCLC Aug 2021 - Aug 2021: Granted for ROS1-positive advanced NSCLC For TKI-naive ROS1-positive NSCLC from TRIDENT-1 study Jan 2021 - Jan 2021: For TKI-naive ROS1-positive NSCLC from TRIDENT-1 study For ROS1+ve metastatic NSCLC based on TRIDENT-1 study Dec 2020 - Dec 2020: For ROS1+ve metastatic NSCLC based on TRIDENT-1 study For 2L treatment of patients with advanced solid tumors Aug 2020 - Aug 2020: For 2L treatment of patients with advanced solid tumors Interim data from P2 portion of P1/2 TRIDENT-1 trial for ROS-1 positive NSCLC and NTRK-positive solid tumors Aug 2020 - Aug 2020: Interim data from P2 portion of P1/2 TRIDENT-1 trial for ROS-1 positive NSCLC and NTRK-positive solid tumors From TRIDENT-1 trial [screenshot] Sep 2019 - Sep 2019: From TRIDENT-1 trial [screenshot] From P1 portion of P1/2 TRIDENT-1 trial for ROS-1 positive NSCLC and NTRK-positive solid tumors Jun 2019 - Jun 2019: From P1 portion of P1/2 TRIDENT-1 trial for ROS-1 positive NSCLC and NTRK-positive solid tumors From P1 portion of P1/2 TRIDENT-1 trial at ASCO 2019 [screenshot] May 2019 - May 2019: From P1 portion of P1/2 TRIDENT-1 trial at ASCO 2019 [screenshot] Interim data for ROS1 fusion +ve NSCLC Sep 2018 - Sep 2018: Interim data for ROS1 fusion +ve NSCLC FromTRIDENT-1 trial for ROS-1 positive NSCLC and NTRK-positive solid tumors [screenshot] Sep 2018 - Sep 2018: FromTRIDENT-1 trial for ROS-1 positive NSCLC and NTRK-positive solid tumors [screenshot] From TRIDENT-1 trial in patients with advanced ALK/ROS1/NTRK+ Cancers at ASCO 2018 [screenshot] Jun 2018 - Jun 2018: From TRIDENT-1 trial in patients with advanced ALK/ROS1/NTRK+ Cancers at ASCO 2018 [screenshot] More	Recruiting	1/2	500	Europe, Canada, Japan, US, RoW	Oral repotrectinib (TPX-0005), repotrectinib	Turning Point Therapeutics, Inc., Zai Lab (Shanghai) Co., Ltd.	Locally Advanced Solid Tumors, Metastatic Solid Tumors	02/28	02/28

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Morise, Masahiro
LIBRETTO-001, NCT03157128 / 2017-000800-59: A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer Jan 2022 - Dec 2022 : Submission for lung cancer Apr 2022 - Dec 2022 : Approval in China for RET+NSCLC, medullary thyroid cancer and thyroid cancer From LIBRETTO-001 trial in RET fusion-positive NSCLC Aug 2020 - Aug 2020: From LIBRETTO-001 trial in RET fusion-positive NSCLC Granted for advanced RET fusion+ve 2L thyroid cancer [LIBRETTO-001] Oct 2018 - Oct 2018: Granted for advanced RET fusion+ve 2L thyroid cancer [LIBRETTO-001] Updated interim data for RET mut medullary & RET fusion thyroid cancers [LIBRETTO-001] Oct 2018 - Oct 2018: Updated interim data for RET mut medullary & RET fusion thyroid cancers [LIBRETTO-001] Granted for 1L RET-mutant medullary thyroid cancer Sep 2018 - Sep 2018: Granted for 1L RET-mutant medullary thyroid cancer Granted for 2L metastatic RET-fusion +ve NSCLC Sep 2018 - Sep 2018: Granted for 2L metastatic RET-fusion +ve NSCLC More	Active, not recruiting	1/2	857	Europe, Canada, Japan, US, RoW	LOXO-292, Selpercatinib, LY3527723	Eli Lilly and Company, Loxo Oncology, Inc.	Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Any Solid Tumor	02/25	02/26
TRIDENT-1, NCT03093116 / 2016-003616-13: A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements Jan 2025 - Jan 2025 : Approval in EU for adv ROS1+ve NSCLC, adv NTRK+ve solid tumors Jan 2023 - Dec 2023 : Data readout from P1/2 TRIDENT-1 trial for ROS1 NSCLC and NTRK+ solid tumors Jul 2023 - Dec 2023 : Approval for ROS1+ NSCLC Jan 2023 - Dec 2023: Approval in US for 2L NSCLC Top line data across ROS1-positive TKI-naïve and TKI-pretreated NSCLC cohorts in TRIDENT-1 trial Apr 2022 - Apr 2022: Top line data across ROS1-positive TKI-naïve and TKI-pretreated NSCLC cohorts in TRIDENT-1 trial NMPA granted in patients with for the treatment of patients with ROS1-positive NSCLC Feb 2022 - Feb 2022: NMPA granted in patients with for the treatment of patients with ROS1-positive NSCLC Presentation of Trident -1 data for the treatment of NSCLC in AACR-NCI-EORTC 2021 Oct 2021 - Oct 2021: Presentation of Trident -1 data for the treatment of NSCLC in AACR-NCI-EORTC 2021 Granted in patients with NTRK-positive, TKI-pretreated advanced solid tumors Oct 2021 - Oct 2021: Granted in patients with NTRK-positive, TKI-pretreated advanced solid tumors Granted for ROS1-positive advanced NSCLC Aug 2021 - Aug 2021: Granted for ROS1-positive advanced NSCLC For TKI-naive ROS1-positive NSCLC from TRIDENT-1 study Jan 2021 - Jan 2021: For TKI-naive ROS1-positive NSCLC from TRIDENT-1 study For ROS1+ve metastatic NSCLC based on TRIDENT-1 study Dec 2020 - Dec 2020: For ROS1+ve metastatic NSCLC based on TRIDENT-1 study For 2L treatment of patients with advanced solid tumors Aug 2020 - Aug 2020: For 2L treatment of patients with advanced solid tumors Interim data from P2 portion of P1/2 TRIDENT-1 trial for ROS-1 positive NSCLC and NTRK-positive solid tumors Aug 2020 - Aug 2020: Interim data from P2 portion of P1/2 TRIDENT-1 trial for ROS-1 positive NSCLC and NTRK-positive solid tumors From TRIDENT-1 trial [screenshot] Sep 2019 - Sep 2019: From TRIDENT-1 trial [screenshot] From P1 portion of P1/2 TRIDENT-1 trial for ROS-1 positive NSCLC and NTRK-positive solid tumors Jun 2019 - Jun 2019: From P1 portion of P1/2 TRIDENT-1 trial for ROS-1 positive NSCLC and NTRK-positive solid tumors From P1 portion of P1/2 TRIDENT-1 trial at ASCO 2019 [screenshot] May 2019 - May 2019: From P1 portion of P1/2 TRIDENT-1 trial at ASCO 2019 [screenshot] Interim data for ROS1 fusion +ve NSCLC Sep 2018 - Sep 2018: Interim data for ROS1 fusion +ve NSCLC FromTRIDENT-1 trial for ROS-1 positive NSCLC and NTRK-positive solid tumors [screenshot] Sep 2018 - Sep 2018: FromTRIDENT-1 trial for ROS-1 positive NSCLC and NTRK-positive solid tumors [screenshot] From TRIDENT-1 trial in patients with advanced ALK/ROS1/NTRK+ Cancers at ASCO 2018 [screenshot] Jun 2018 - Jun 2018: From TRIDENT-1 trial in patients with advanced ALK/ROS1/NTRK+ Cancers at ASCO 2018 [screenshot] More	Recruiting	1/2	500	Europe, Canada, Japan, US, RoW	Oral repotrectinib (TPX-0005), repotrectinib	Turning Point Therapeutics, Inc., Zai Lab (Shanghai) Co., Ltd.	Locally Advanced Solid Tumors, Metastatic Solid Tumors	02/28	02/28